MedTrace Logo

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2025-09-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Conditions

  • Epstein-Barr Virus Infection

Interventions

BIOLOGICAL

mRNA-1195.1

Sterile liquid for injection

BIOLOGICAL

mRNA-1195.2

Sterile liquid for injection

BIOLOGICAL

mRNA-1189

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

BIOLOGICAL

mRNA-1195

Sterile liquid for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-05
Primary Completion
2026-10-07
Completion
2026-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05831111 on ClinicalTrials.gov